Stock Track | Moderna Soars 6.94% Intraday on Pipeline Catalysts and Flu Vaccine Approval Expectations

Stock Track07-02 21:51

Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.

The stock's upward movement follows the company's recent Science Day event where it disclosed its in vivo CAR-T project mRNA-6007 targeting B-cell mediated autoimmune diseases, with plans to enter clinical trials next year. Moderna also showcased multiple pipeline assets including tumor vaccines, cancer prevention vaccines, and an AI-driven R&D platform, fueling market expectations for the company's transition from a single-product vaccine maker to a platform biotechnology company.

Additional catalysts include the unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee for Moderna's seasonal flu vaccine candidate mRNA-1010, with a final regulatory decision expected by August 5. These developments prompted analyst upgrades, with Piper Sandler raising its price target to $77 from $69 while maintaining an Overweight rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121610629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121610629","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars 6.94% Intraday on Pipeline Catalysts and Flu Vaccine Approval Expectations","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.</p><p>The stock's upward movement follows the company's recent Science Day event where it disclosed its in vivo CAR-T project mRNA-6007 targeting B-cell mediated autoimmune diseases, with plans to enter clinical trials next year. Moderna also showcased multiple pipeline assets including tumor vaccines, cancer prevention vaccines, and an AI-driven R&D platform, fueling market expectations for the company's transition from a single-product vaccine maker to a platform biotechnology company.</p><p>Additional catalysts include the unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee for Moderna's seasonal flu vaccine candidate mRNA-1010, with a final regulatory decision expected by August 5. These developments prompted analyst upgrades, with Piper Sandler raising its price target to $77 from $69 while maintaining an Overweight rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 6.94% Intraday on Pipeline Catalysts and Flu Vaccine Approval Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 6.94% Intraday on Pipeline Catalysts and Flu Vaccine Approval Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-02 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.</p><p>The stock's upward movement follows the company's recent Science Day event where it disclosed its in vivo CAR-T project mRNA-6007 targeting B-cell mediated autoimmune diseases, with plans to enter clinical trials next year. Moderna also showcased multiple pipeline assets including tumor vaccines, cancer prevention vaccines, and an AI-driven R&D platform, fueling market expectations for the company's transition from a single-product vaccine maker to a platform biotechnology company.</p><p>Additional catalysts include the unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee for Moderna's seasonal flu vaccine candidate mRNA-1010, with a final regulatory decision expected by August 5. These developments prompted analyst upgrades, with Piper Sandler raising its price target to $77 from $69 while maintaining an Overweight rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1121610629","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121610629","pubTimestamp":1783000292,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.The stock's upward movement follows the company's recent Science Day event...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股赛道|Moderna盘中大涨6.94%，受管线催化剂及流感疫苗获批预期影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) experienced a significant intraday surge, with shares soaring 6.94% during Thursday's trading session.The stock's upward movement follows the company's recent Science Day event where it disclosed its in vivo CAR-T project mRNA-6007 targeting B-cell mediated autoimmune diseases, with plans to enter clinical trials next year. Moderna also showcased multiple pipeline assets including tumor vaccines, cancer prevention vaccines, and an AI-driven R&D platform, fueling market expectations for the company's transition from a single-product vaccine maker to a platform biotechnology company.Additional catalysts include the unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee for Moderna's seasonal flu vaccine candidate mRNA-1010, with a final regulatory decision expected by August 5. These developments prompted analyst upgrades, with Piper Sandler raising its price target to $77 from $69 while maintaining an Overweight rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121610629","isCrawlerRequest":true}